Macquarie said that Illumya, Sun Pharma’s largest product, generates a meaningful portion of its revenue from Medicare Part B. This raises the likelihood that the drug could fall within the scope of the proposed GLOBE model.
Macquarie said that Illumya, Sun Pharma’s largest product, generates a meaningful portion of its revenue from Medicare Part B. This raises the likelihood that the drug could fall within the scope of the proposed GLOBE model.